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Background: The gene encoding the serine biosynthesis pathway enzyme PHGDH is located in a region of focal
genomic copy number gain in human cancers. Cells with PHGDH amplification are dependent on enzyme expression
for proliferation. However, dependence on increased PHGDH expression extends beyond production of serine alone,
and further studies of PHGDH function are necessary to elucidate its role in cancer cells. These studies will require a
physiologically relevant form of the enzyme for experiments using engineered cell lines and recombinant protein.
Results: The addition of an N-terminal epitope tag to PHGDH abolished the ability to support proliferation of
PHGDH-amplified cells despite retention of some activity to convert 3-PG to PHP. Introducing an R236E mutation
into PHGDH eliminates enzyme activity, and this catalytically inactive enzyme cannot support proliferation of
PHGDH-dependent cells, arguing that canonical enzyme activity is required. Tagged and untagged PHGDH exhibit
the same intracellular localization and ability to produce D-2-hydroxyglutarate (D-2HG), an error product of PHGDH,
arguing that neither mislocalization nor loss of D-2HG production explains the inability of epitope-tagged PHGDH to
support proliferation. To enable studies of PHGDH function, we report a method to purify recombinant PHGDH and
found that untagged enzyme activity was greater than N-terminally tagged enzyme. Analysis of tagged and untagged
PHGDH using size exclusion chromatography and electron microscopy found that an N-terminal epitope tag alters
enzyme structure.
Conclusions: Purification of untagged recombinant PHGDH eliminates the need to use an epitope tag for enzyme
studies. Furthermore, while tagged PHGDH retains some ability to convert 3PG to PHP, the structural alterations caused
by including an epitope tag disrupts the ability of PHGDH to sustain cancer cell proliferation.
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Flux through the pathway that synthesizes serine from
glucose is important for proliferation of some cancer cells.
D-3-phosphoglycerate dehydrogenase (PHGDH) catalyzes
the first reaction in serine biosynthesis. Using NAD+ as a
cofactor, PHGDH oxidizes the glycolytic intermediate 3-
phosphoglycerate (3-PG) to phosphohydroxypyruvate (PHP)
(Figure 1A). Subsequent steps in serine biosynthesis involve* Correspondence: mvh@mit.edu
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unless otherwise stated.phosphoserine aminotransferase 1 (PSAT1)-catalyzed
transamination of PHP and glutamate to phosphoserine
(P-Ser) and alpha-ketoglutarate (αKG), followed by
phosphoserine phosphatase (PSPH)-mediated dephos-
phorylation of P-Ser to produce serine. Serine has mul-
tiple fates in cells, serving as an amino acid for protein
synthesis and a precursor for lipid head groups. Serine
can also be further metabolized to glycine by serine
hydroxymethyltransferase, which donates a one-carbon
unit to the folate pool for nucleotide synthesis and
methyltransferase reactions. In addition to its role as an
amino acid, glycine also contributes to nucleotidel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 N-terminal epitope-tagged PHGDH cannot support cell proliferation following PHGDH knockdown. (A) Schematic representation of
the serine biosynthesis pathway. 3-PG, 3-phosphoglycerate; PHGDH, 3-phosphoglycerate dehydrogenase; NAD+/NADH, oxidized and reduced forms of
nicotinamide adenine dinucleotide, respectively; PHP, phosphohydroxypyruvate; PSAT, phosphoserine aminotransferase; Glu, glutamate; αKG, alpha-
ketoglutarate; P-Ser, phosphoserine; PSPH, phosphoserine phosphatase; Ser, serine. (B) Cell number over time of PHGDH-amplified T.T. cells stably expressing
either an shRNA-resistant FLAG-His-PHGDH cDNA or empty vector (EV) control. (C)Western blot analysis assessing knockdown of endogenous PHGDH and
expression of FLAG-His-PHGDH cDNA. (D)Western blot analysis of T.T. cells stably expressing an shRNA-resistant PHGDH cDNA (untagged) or empty vector
(EV) control. (E) Cell number over time of the cells described in (D) when infected with virus expressing GFP or PHGDH shRNA. Error bars show
standard deviation from the mean.
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the biosynthesis of serine from glucose plays a central
role in cancer cell metabolism.
PHGDH expression is important in human cancers.
PHGDH is located in a region of genomic copy number
gain that includes four other genes in the smallest com-
mon amplified region [2]. PHGDH copy number gain has
been observed with the highest frequency in melanoma
and breast cancer, and PHGDH-amplified cell lines aredependent on enzyme expression to proliferate in culture
[3,4]. Increased expression of PHGDH and other serine
biosynthesis pathway enzymes is found in other cancer
contexts as well, with evidence that c-Myc [5], ATF4
[6], and the lysine methyltransferase G9A [7] increase
PHGDH expression via transcriptional and epigenetic
mechanisms. Increased activity of serine biosynthesis
pathway enzymes has been hypothesized to support in-
creased nucleotide biosynthesis in cancer [8], although
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sion for growth as xenograft tumors [4,9].
Studies have also demonstrated that exogenous serine is
critical for tumor cell proliferation in vitro and as xeno-
grafts [10-12]; however, there may be a distinct requirement
for de novo serine synthesis from glucose even in the pres-
ence of abundant serine. Exogenous serine does not rescue
proliferation of PHGDH-amplified cells following knock-
down of PHGDH expression [4,9]; moreover, the expres-
sion of PSAT and PSPH is also required for the continued
proliferation of at least some of these cells [3]. Taken
together, these data suggest that flux through the serine bio-
synthesis pathway is important for cell metabolism beyond
providing serine. One possibility is a role in TCA cycle ana-
pleurosis [4], but it remains controversial whether this un-
derlies the requirement for PHGDH in all cells [2,3,13].
Interrogating PHGDH function(s) would benefit from
studies of purified enzyme. Past comprehensive studies
of PHGDH enzyme activity examined the Escherichia
coli protein [14-17], which has a different domain struc-
ture than the human enzyme [18]. Structural studies of
the human enzyme are limited to a truncated protein
(PDB 2G76, unpublished), and enzymatic analysis often
uses epitope-tagged protein [19,20]. While epitope tags
are commonly used to isolate recombinant enzyme, in
some cases, these tags can alter structure and/or function
[21]. Therefore, both an understanding of whether an epi-
tope tag will impact PHGDH function and methods to
produce recombinant enzyme that reflects endogenous
protein activity in cells are necessary to determine the role
of PHGDH in human cancer and normal tissues.
We observed that, unlike untagged protein, the ex-
pression of PHGDH with an epitope tag was unable to
rescue cell proliferation following PHGDH knockdown in
PHGDH-amplified cells. An enzymatically dead PHGDH
mutant also failed to rescue proliferation of cells following
PHGDH knockdown, suggesting that enzyme activity is
required for cells to proliferate. We present a method for
purification of untagged recombinant PHGDH and find
that the activity of this protein is appreciably greater than
recombinant PHGDH with an N-terminal epitope tag.
Finally, we show using size exclusion chromatography and
electron microscopy that an N-terminal epitope tag on
PHGDH affects protein structure, which may contribute
to an inability to substitute for endogenous PHGDH in
cells. These data argue that the use of epitope tags should
be avoided in future studies of PHGDH function.Methods
Cell culture, viral infection, and assessment of cell
proliferation
Cells were cultured in DMEM supplemented with 10%
FBS, penicillin, and streptomycin. We stably introducedshRNA-resistant PHGDH cDNAs into cells using the
retroviral vector pLHCX and selected with 150 μg/ml hygro-
mycin. To decrease PHGDH expression, shRNA construct
TRCN0000028548 with target sequence 5′-AGGTGATAA
CACAGGGAACAT-3′ was used. Cells were infected with
lentivirus to express shRNAs, selected for 3 days in 1 μg/ml
puromycin and proliferation assessed on subsequent days.
Western blot analysis
PHGDH protein was detected using a rabbit polyclonal
anti-PHGDH antibody from Sigma, St. Louis, MO, USA
(HPA021241) at 0.2 μg/ml and actin detected using a rabbit
polyclonal anti-actin antibody from Abcam, Cambridge, MA,
USA (ab1801) at 1 μg/ml, appropriate HRP-conjugated
secondary antibodies and chemiluminescence.
Site-directed mutagenesis
The PHGDH R236E mutant was generated using the
QuickChange II XL Site-Directed Mutagenesis Kit from
Agilent, Santa Clara, CA, USA, with the following primers:
5′-TGTGGTGAACTGTGCCGAGGGAGGGATCGTGGA
CG-3′ and 5′-CGTCCACGATCCCTCCCTCGGCACAGT
TCACCACA-3′. To generate shRNA-resistant PHGDH, we
used the same kit and the following primers: 5′-CCCAAA
GGGACCATCCAAGTTATCACACAGGGAACATCCC-
3′ and 5′-GGGATGTTCCCTGTGTGATAACTTGGATG
GTCCCTTTGGG-3′.
Purification of epitope-tagged PHGDH and PSAT proteins
pTriEx-3 FLAG-His-PHGDH (wild type or R236E mutant)
or pET28a His-PHGDH was transformed into BL21 (DE3)
E. coli. Single colonies from these plates were inoculated
into LB plus ampicillin (pTriEx-3) or kanamycin (pET28a)
and grown at 37°C and 225 rpm overnight. The next day,
cultures were diluted 1:40 and grown to OD600 = 0.4, and
then 0.5 mM IPTG was added before incubating at 16°C
and 225 rpm overnight. The bacteria were pelleted at
6,000 × g for 15 min, and the pellet was flash frozen and
stored at −80°C. All protein purification steps were per-
formed at 4°C. To purify protein, bacterial pellets were re-
suspended in 30 ml lysis buffer (50 mM Tris, pH 8.5, 10
mM MgCl2, 300 mM NaCl, 10% glycerol, and 5 mM imid-
azole) and sonicated, and the lysate was centrifuged at
20,000 × g for 45 min. β-Mercaptoethanol (30 μl) was added
and the lysate mixed with 3 ml of Ni-NTA agarose (Qiagen,
Hilden, Germany) in wash buffer (50 mM Tris, pH 8.5, 10
mMMgCl2, 300 mM NaCl, 10% glycerol, and 30 mM imid-
azole). This mixture was shaken gently for 2 to 3 h, and
Ni-NTA beads were pelleted and washed four times with
wash buffer. The beads and lysate were transferred to an
empty column and protein recovered in elution buffer (50
mM Tris, pH 8.5, 10 mM MgCl2, 250 mM NaCl, 10% gly-
cerol, and 250 mM imidazole) with 1-ml fractions collected.
Those fractions with high protein content were determined
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were pooled and separated on a GE HiPrep Sephacryl
S-200 HR column (GE Healthcare Bio-Sciences, Pittsburgh,
PA, USA) using an AKTA FPLC system (GE Healthcare
Bio-Sciences, Pittsburgh, PA, USA). The column was run at
0.5 ml/min for one-column volume in storage buffer (20
mM Tris, pH 7.5, 100 mM NaCl, 1 mM TCEP). Fractions
were collected from the void volume to the elution volume
of a 17-kDa standard. UV absorbance was used to deter-
mine those fractions with the highest protein concentra-
tion, and those were pooled, 0.5 mM betaine added, and
concentrated to 5 to 10 μg/μl purified protein. Fractions
from the size exclusion column were later analyzed by
SDS-PAGE and Coomassie staining. After destaining,
Coomassie-stained gels were imaged on a LiCOR and
quantitated by densitometry analysis using ImageJ. Recom-
binant His-tagged PSAT was generated by an analogous
procedure, with differences as follows. pET28a His-PSAT
was transformed into BL21 (DE3) E. coli, grown as de-
scribed above to an OD600 of 0.7, then 0.5 mM IPTG was
added, and the culture was grown at room temperature
and 225 rpm for 6 h. After rPSAT was eluted from the Ni-
NTA agarose beads, the combined fractions were dialyzed
into 50 mM Tris, pH 7.5, 10 mM MgCl2, 25 mM NaCl,
20% glycerol, 0.15% beta-mercaptoethanol.
Preparation of Cibacron Blue F3GA Sepharose
This protocol was modified from [22]. Sixty milliliters of
GE Sepharose CL-4B resin (GE Healthcare Bio-Sciences,
Pittsburgh, PA, USA) in water was mixed with 8.6 ml of 45
mg/ml Cibacron Blue F3GA (Polysciences, Warrington,
PA, USA) for 30 min at room temperature. Twenty-seven
milliliters of 2 M sodium sulfate were added, followed by
30 min more mixing at room temperature. Two hundred
ninety microliters of 10 M NaOH was added slowly, drop-
wise with mixing. The resulting bead suspension was mixed
at 60°C for 2 h before neutralizing with 15 ml of 2.5 M so-
dium phosphate buffer, pH 7.5. The beads were washed
and then stored in 20% ethanol at 4°C for at least 2 days.
Two batches of beads were subsequently mixed and used
to fill an empty GE XK 26/40 column (GE Healthcare
Bio-Sciences, Pittsburgh, PA, USA) to a column volume
of 65 ml and attached to an AKTA FPLC system.
Purification of untagged PHGDH protein
pET28a PHGDH was transformed into BL21 E. coli. From
a single colony, a culture was grown to an OD600 = 0.4, 0.5
mM IPTG added, and the culture incubated at room
temperature and 225 rpm for 6 h. The bacteria were flash
frozen, thawed, and resuspended in 50 ml buffer A (50
mM HEPES pH 8.0, 1 mM EDTA) plus 1 mM DTT and
protease inhibitors (Roche). This suspension was soni-
cated and centrifuged at 20,000 × g for 45 min, and the
supernatant was loaded onto an F3GA column preparedas described above. The column was run at a flow rate of 2
ml/min as follows: 200 ml buffer A, 10-ml linear gradient to
60% buffer B (50 mM HEPES, pH 8.0, 1 mM EDTA, 400
mM KCl), 130 ml 60% buffer B. During the gradient and
60% B wash, 10-ml fractions were collected. Fractions were
assessed for the presence of the recombinant protein by UV
absorbance, pooled, concentrated, and desalted into buffer
A. The resulting solution was fractionated on a GE MonoQ
HR 10/10 column (GE Healthcare Bio-Sciences, Pittsburgh,
PA, USA) using an AKTA FPLC at a flow rate of 0.5 ml/min
as follows: 30 ml buffer A, 45-ml linear gradient to 45% buf-
fer B, 125 ml 45% buffer B. During the 45% B wash, 2-ml
fractions were collected. Fractions were assessed for recom-
binant protein using UV absorbance, pooled and further sep-
arated using GE HiPrep Sephacryl S-200 HR column. The
column fractions were treated and analyzed as described for
epitope-tagged protein to produce the final protein solution.
Assessment of PHGDH activity
A linked assay was utilized where PHGDH, PSAT, and all
substrates were mixed in a well of a 96-well plate and activ-
ity assessed at 37°C. The reaction buffer used was 300 mM
Tris, pH 9, 1 mM EDTA, 1 mM TCEP, 0.025% BSA. A
linked assay with PSAT was used to interrogate 3-PG and
NAD+ to PHP and NADH conversion by PHGDH because
the equilibrium of this reaction lies toward 3-PG [23]. En-
zyme activity was measured by following NADH generation
over time by fluorescence, with excitation at 340 nm and
emission at 460 nm. All substrates were present in excess of
their reported KM values (final concentration 10 mM each
3-PG, NAD+, and Glu). PSAT was present in excess of
PHGDH and control experiments performed to ensure that
PSAT was not limiting during the kinetic window evaluated.
Immunofluorescence and confocal microscopy
Cells were grown on glass coverslips and fixed with 4%
paraformaldehyde. Cells were then permeabilized with PBS
containing 0.1% Tween 20, blocked in 1% BSA, and incu-
bated in primary antibody overnight at 4°C. Primary anti-
body was rabbit polyclonal anti-PHGDH antibody from
Sigma (HPA021241), used at 0.01 μg/ml. Secondary anti-
body was AlexaFluor594 donkey anti-rabbit (A21207, Life
Technologies, Grand Island, NY, USA) at 2 μg/ml. Cells
were counterstained with DAPI (D9542, Sigma, St. Louis,
MO, USA) and mounted using Prolong Gold Antifade
mounting medium (P36934, Life Technologies, Grand
Island, NY, USA). Images were captured using a Deltavi-
sion Spectris imaging system (GE Healthcare BioSciences
Corp., Piscataway, NJ, USA) with × 100 oil immersion ob-
jective and analyzed using softWoRx (Applied Precision,
Issaquah, WA, USA) and ImageJ (National Institutes of
Health) software. Total fluorescence intensity was cor-
rected using a secondary antibody-only control and stain-
ing of PHGDH knockout cell lines.
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Cells were extracted in ice cold 1:4:5 water:methanol:-
chloroform with valine-D8 as an internal standard. The
aqueous layer was dried under N2 and analyzed by LC/
MS using a Q Exactive benchtop orbitrap mass spec-
trometer (Thermo Fisher Scientific, San Jose, CA, USA)
equipped with a heated electrospray ionization (HESI)
probe, coupled to a Dionex UltiMate 3000 UPLC system
(Thermo Fisher Scientific, San Jose, CA, USA). For ana-
lysis, dried metabolites were resuspended in 100 μl
water, and 1 μl of each sample was separated on a ZIC-
pHILIC 2.1 × 150 mm (5-μm particle size) column
(EMD) at a flow rate of 0.150 ml/min as follows: 0 to 20
min: linear gradient from 80% to 20% B; 20 to 20.5 min:
linear gradient from 20% to 80% B; and 20.5 to 28 min:
hold at 80% B. Buffer A was 20 mM ammonium carbon-
ate, 0.1% ammonium hydroxide; buffer B was acetonitrile.
Metabolites were detected by mass spectrometry operat-
ing in full-scan, polarity switching mode with the spray
voltage set to 3.0 kV, the heated capillary held at 275°C,
and the HESI probe held at 350°C. The sheath gas flow
was set to 40 units, the auxiliary gas flow was set to 15
units, and the sweep gas flow was set to 1 unit. The MS
data acquisition was performed in a range of 70 to 1,000
m/z, with the resolution set at 70,000, the AGC target at
106, and the maximum injection time at 80 ms. Relative
quantitation of polar metabolites was performed with
XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific, San
Jose, CA, USA) using a 5 ppm mass tolerance and referen-
cing an in-house library of chemical standards.
Size exclusion chromatography
Either recombinant His-PHGDH or recombinant un-
tagged PHGDH was analyzed using a GE HiPrep Sepha-
cryl S-200 HR column. The column was run at 0.5 ml/
min for one-column volume in storage buffer. Fractions
were collected from just before the void volume to the
elution volume of a 17-kDa standard. Fractions were then
subjected to SDS-PAGE, and the gels were stained with
colloidal Coomassie. After destaining, the gel was imaged
and quantitated as described above.
Electron microscopy and image processing
Specimens were prepared using 12 ng/μl His-PHGDH
and 15 ng/μl untagged PHGDH with 0.5 mM NADH by
adsorbing 5 μl for approximately 1 min to carbon-coated
EM grids that had been glow discharged immediately
before use, negative staining with 2% uranyl acetate,
sandwiching under a second layer of carbon film, blot-
ting, and drying [24]. On an FEI Tecnai Spirit BioTwin
microscope (FEI Tecnai, Hillsboro, OR, USA) with a tung-
sten filament and an AMT XR16 CCD detector, 103 im-
ages of the untagged PHGDH preparation and 107 images
of the His-PHGDH preparation were acquired at 0.5- to1.0-μm defocus (assessed using CTFFIND3 [25] imple-
mented in SPIDER [26]). Identical microscope and camera
settings were used for imaging both specimens: ×60,000
magnification (1.84 Å/pixel at the specimen level), 80-kV
acceleration voltage, and 1.6-s exposure.
Particles were selected with e2boxer from eightfold binned,
band-pass-filtered images. The 23,568 PHGDH particles and
30,894 His-PHGDH particles were cut from the original full-
sized images into windows of 160 × 160 pixels using
EMAN2 [27]. In preparation for processing, particle images
were high-pass filtered, outlier densities median filtered,
downsampled fivefold to 32-pixel squares of 9.20 Å/pixel,
and normalized such that background densities were scaled
to 0 ± 1. Particles from each dataset were aligned, clustered,
and realigned within clusters with SPARX using identical
reference-free alignment (sxali2d) and k-means clustering
(sxkmeans) parameters [28]. To sort averages according to
particle size, averages were binarized at a threshold (0.25)
that distinguishes the background gray values from the fore-
ground particle densities. Distributions of particle sizes were
plotted with Gnuplot. Kolmogorov-Smirnov statistical tests
for size distributions of the two samples were calculated
using the stats module of SciPy and corroborated with Prism
(GraphPad Software).
Results
Untagged PHGDH, but not N-terminally tagged PHGDH,
can rescue cell proliferation following PHGDH knockdown
Knockdown of PHGDH expression using any of several
different small hairpin RNAs impairs proliferation of
PHGDH-amplified cell lines [3,4]. However, even when mul-
tiple hairpins are used, off-target effects can complicate inter-
pretation of results from RNA interference experiments [29].
To confirm that loss of PHGDH expression decreases pro-
liferation of PHGDH-amplified cells, we introduced silent
mutations into the PHGDH cDNA to render it resistant to
shRNA-mediated knockdown. Initially, an N-terminal
FLAG-His epitope tag was included for ease of protein de-
tection and purification. To determine whether FLAG-His-
PHGDH expression can rescue shRNA-mediated knock-
down of endogenous PHGDH expression, T.T. cells were
engineered to express either shRNA-resistant PHGDH
cDNA or empty vector as a control. Proliferation of T.T.
cells, an esophageal cancer cell line with PHGDH copy
number gain, has been shown previously to be sensitive to
stable knockdown of PHGDH expression [3]. Consistent
with previous studies, stable knockdown of PHGDH in
control T.T. cells impaired proliferation (Figure 1B). How-
ever, exogenous expression of tagged PHGDH failed to res-
cue this decrease in cell proliferation despite the presence
of tagged PHGDH protein (Figure 1B,C). To determine
whether exogenously expressed PHGDH failed to rescue
proliferation because the epitope tag interfered with protein
function, T.T. cells were engineered to express shRNA-
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Expression of PHGDH without an epitope tag rescued pro-
liferation following knockdown of PHGDH (Figure 1E), in
agreement with findings in other cells [9]. These findings
suggest that introduction of an N-terminal epitope tag
impairs the ability of PHGDH to support T.T. cell
proliferation.PHGDH enzymatic activity is required to rescue cell
proliferation following PHGDH knockdown
Despite an inability to rescue proliferation, recombinant
FLAG-His-PHGDH exhibits enzyme activity in vitro
(Figure 2A). PHGDH enzyme activity was measured by
tracking NADH production when NAD+ and 3-PG were
provided at saturating concentrations, with the product PHP
removed by coupling the assay to PSAT and providing glu-
tamate (Figure 1A). To confirm that the ability of exogenous
PHGDH to rescue endogenous PHGDH knockdown is
dependent on enzymatic activity, we generated a mutant
that was predicted to be enzymatically inactive. The posi-
tively charged arginine residue at position 236 of PHGDH is
thought to anchor the carboxyl group of 3-PG. R236 in
human PHGDH is analogous to R240 in E. coli PHGDH,Figure 2 PHGDH enzymatic activity is required for cell proliferation fo
tracking NADH production by fluorescence. The assay was performed at sa
PHGDH-amplified T.T. cells stably expressing shRNA-resistant PHGDH wild ty
when infected with virus expressing GFP or PHGDH shRNA. Error bars showwhich when replaced with an alanine was effective at dis-
rupting bacterial enzyme function [16]. Thus, we deter-
mined whether mutation of R236 in human PHGDH to a
negatively charged glutamate would disrupt enzyme func-
tion. FLAG-His-PHGDH R236E was purified from E. coli
and had no enzyme activity in vitro (Figure 2A). We stably
overexpressed an shRNA-resistant, untagged version of
the R236E mutant in T.T. cells and found that it was in-
capable of rescuing cell proliferation following knockdown
of endogenous PHGDH (Figure 2B and Additional file 1:
Figure S1). These data support PHGDH enzymatic
function being required for the proliferation of T.T. cells.Purification of untagged PHGDH
To study the differences between tagged and untagged
PHGDH in vitro, we developed a method to purify the un-
tagged protein. Dye-based pseudoaffinity ligands have been
useful for purification of many other enzymes [30,31]. An
evaluation of dye-based ligands that bound other enzymes
that use NAD(H) as a co-substrate identified Cibacron Blue
F3GA as a pseudoaffinity ligand capable of enriching
PHGDH protein expressed in E. coli from other proteins by
severalfold (Figure 3A). We then designed a purificationllowing PHGDH knockdown. (A) In vitro enzyme activity assessed by
turating substrate concentrations. (B) Cell number over time for
pe or R236E (enzymatically dead) cDNAs or empty vector (EV) control
standard deviation from the mean.
Figure 3 Purified untagged recombinant PHGDH has higher specific activity than N-terminally tagged PHGDH. (A) Coomassie gel of
rPHGDH (untagged) after each step of the purification: 1. cleared lysate from E. coli expressing rPHGDH protein, 2. eluate from Cibacron Blue
F3GA column, 3. eluate from anion exchange column, 4. eluate from size exclusion column, and 5. rFLAG-His-PHGDH purified by sequential nickel
and size exclusion columns, for comparison. Molecular weight standards in kilodaltons are present to the left of lane 1. (B) In vitro enzyme activity
of untagged rPHGDH. Assay was performed at saturating substrate concentrations. (C) Comparison of relative specific activity of rPHGDH and
rHis-PHGDH. Error bars show standard deviation from the mean.
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affinity chromatography using F3GA binding, ion exchange
chromatography, and size exclusion chromatography. Using
this approach, we recover E. coli-expressed PHGDH protein
to the same approximate level of purity as His-FLAG-tagged
PHGDH prepared using Ni-based affinity chromatography
and size exclusion chromatography (Figure 3A).
Untagged recombinant PHGDH has higher specific
activity than N-terminally tagged PHGDH
Untagged recombinant protein is active and has linear kin-
etics in an in vitro assay. The absolute specific activity of
untagged PHGDH under these conditions is 0.071 ± 0.001
nmol NADH produced/s/μg protein (Figure 3B). This spe-
cific activity is twice the specific activity of recombinant His-
PHGDH (Figure 3C), which again exhibits about twice the
relative specific activity of recombinant FLAG-His-PHGDH
(Additional file 2: Figures S2A, B).
N-terminally tagged and untagged PHGDH display the
same intracellular localization
To determine if the epitope tag disrupts PHGDH loca-
lization, MDA-MB-231 cells, which express very little
PHGDH [4], and PHGDH-amplified T.T. cells were
engineered to express vector alone, untagged PHGDH,
or FLAG-His-PHGDH and the spatial distribution of
PHGDH determined by immunofluorescence. As ex-
pected, MDA-MB-231 cells expressing empty vector
control showed very little PHGDH staining. In all other
samples, PHGDH showed widespread cytoplasmic stain-
ing with no difference observed when epitope-tagged
PHGDH was introduced (Figure 4A,B). These data are
consistent with N-terminally tagging PHGDH having
no effect on enzyme localization and argue that an ef-
fect on localization does not explain the inability of
tagged PHGDH to support cell proliferation.Figure 4 N-terminal epitope-tagged and untagged PHGDH display
the same intracellular localization. (A) MDA-MB-231 cells, which are
PHGDH low, and (B) PHGDH-amplified T.T. cells expressing either
vector control, untagged, or N-terminally tagged PHGDH were
stained for PHGDH immunofluorescence.Cells expressing N-terminally tagged and untagged
PHGDH have an equal 2HG:αKG ratio
In addition to catalyzing 3-PG conversion to PHP, PHGDH
from both E. coli and humans can also produce D-2-
hydroxyglutarate (D-2HG) as a minor product [13,32]. Be-
cause D-2HG has been implicated in the pathogenesis of
some human cancers we examined whether N-terminally
tagged PHGDH results in lower 2HG production than wild-
type PHGDH in cells. We measured the 2HG:αKG ratio
of T.T. and MDA-MB-231 cells expressing either N-
terminally tagged or untagged PHGDH by LC/MS. In
both cell lines, 2HG:αKG ratios were not significantly
different regardless of which enzyme was expressed
(Additional file 3: Figure S3), suggesting that N-
terminally tagged PHGDH produces the same amount
of 2HG as untagged PHGDH in cells.N-terminally tagged and untagged PHGDH exhibit
different structural properties by size exclusion analysis
To interrogate structural differences that might exist be-
tween the tagged and untagged recombinant protein, we
assessed the mobility of each by size exclusion chroma-
tography. We found that the elution volume for tagged
versus untagged PHGDH differed appreciably, with
rHis-PHGDH eluting much closer to the void volume of
a Sephacryl S-200 HR column (GE Healthcare Bio-
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lar proteins from 5 to 250 kDa (Figure 5). Comparison
with standards of known molecular mass indicates that
the peak of untagged PHGDH is approximately 155 kDa,
whereas the peak of His-PHGDH is approximately 240
kDa. These data argue that an N-terminal tag affects the
mobility of PHGDH on a size exclusion column, and this
change in structure may affect the ability of the enzyme
to support cell proliferation in some cancer cells.N-terminally tagged PHGDH forms larger macromolecular
complexes than untagged PHGDH
To further evaluate potential differences in the structure of
the tagged and untagged recombinant protein, negatively
stained specimens of each purified protein were prepared
and imaged by transmission electron microscopy and pro-
tein particles were analyzed by standard methods for align-
ment and clustering. Comparing the class averages from
the PHGDH and His-PHGDH specimens suggests thatFigure 5 N-terminal epitope-tagged and untagged PHGDH exhibit
different mobility on size exclusion chromatography. Relative
amount of rPHGDH and rHis-PHGDH protein present in fractions eluted
from a Sephacryl S-200 size exclusion column. The 158- and 44-kDa
standards are shown for comparison, with the column void volume
represented in fraction 2.both preparations have overlapping macromolecular sizes
and shapes (Figure 6A,B). To quantitatively assess whether
the distribution of particle sizes are different, the area of
each average was calculated and compared between
PHGDH and His-PHGDH (Figure 6C). The His-PHGDH
particle size distribution is significantly shifted toward
more massive species (P value <0.0001) with a substan-
tial population of particles of size greater than 11,000 Å2.
The altered distribution is reflected in increased mean par-
ticle size of His-PHGDH (8,922 Å2) relative to PHGDH
(7,855 Å2). Given the estimated masses of the complex
from size exclusion chromatography, these areas are
about twice what would be expected for a dimer, trimer,
or tetramer, suggesting that the oligomeric structures of
human PHGDH are not approximated well by a sphere.
This data demonstrates directly that an N-terminal epi-
tope tag affects the PHGDH structure, which may in turn
influence the activity of the protein in vitro and the ability
to support proliferation after knockdown of the endogen-
ous enzyme.
Discussion
We demonstrate that N-terminally tagged PHGDH is
not functionally equivalent to endogenous PHGDH. Epi-
tope tags have been used for more than 25 years [33-36]
and are useful for both purification of recombinant pro-
teins and protein detection when antibodies to an en-
dogenous protein are not available. Although many tags
are well tolerated [21], introducing an exogenous peptide
sequence onto the N-terminus of PHGDH disrupts pro-
tein structure and function. High-quality antibodies for
PHGDH are available, and a scheme for PHGDH purifi-
cation using commercially available materials is de-
scribed here that renders the use of epitope tags on
PHGDH unnecessary.
N-terminally tagged PHGDH not only retains some
enzymatic activity in vitro but also exhibits structural
differences from the endogenous protein; understanding
how the tag disrupts PHGDH structure and function
could provide new insight into how this protein supports
cell proliferation. There is no atomic-resolution struc-
ture of the full-length human PHGDH protein, and
more detailed structural information would aid in under-
standing why an N-terminal tag perturbs PHGDH func-
tion. PHGDH enzymes from various organisms are
grouped into three types (types I to III) based on differ-
ences in C-terminal domains thought to be involved in
enzyme regulation [37]. All type I and II PHGDH en-
zymes examined, including E. coli [17], M. tuberculosis
[38], chicken [15], rat [39], and rabbit [40] form tetra-
mers. The inter-subunit interfaces in both type I and II
enzymes contain contacts involving the C-terminal regula-
tory domains. As a result, type III enzymes that lack a C-
terminal domain form dimers [37,38]. Human PHGDH is
Figure 6 N-terminally tagged PHGDH forms larger macromolecular complexes than untagged PHGDH. (A) Representative images
obtained from PHGDH and His-PHGDH specimens. Scale bar = 100 nm. (B) Montage of class averages of PHGDH and His-PHGDH sorted from
smallest (top row) to largest (bottom row). Each average is 294 Å wide at the specimen level. (C) Normalized particle-size distributions (particles
per bin/total particles) are displayed as histograms (dashed lines) and as smoothed curves (solid lines) for PHGDH (blue) and His-PHGDH (red).
The His-PHGDH and PHGDH histograms are offset by 42 Å2 to avoid overlapping lines.
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tetramer; however, the only human PHGDH structure is
of a truncated protein lacking the C-terminal domains
and thus crystallized as a dimer (PDB 2G76, unpublished).
Despite dimeric type III enzymes retaining catalytic func-
tion, all plant and animal PHGDH enzymes characterized
so far are type I [18,41], suggesting that the C-terminal
regulatory domains are important for PHGDH function in
these cells.
Few full-length type I and II PHGDH protein struc-
tures have been solved; however, examples of both are
available. The E. coli protein is an example of a type II
PHGDH with a known structure and is a symmetrical
dimer of dimers in which all monomers assume an iden-
tical configuration. In E. coli PHGDH, one dimer inter-
face is formed by two adjacent nucleotide binding
domains and the other is formed by two C-terminalregulatory domains [17] (PDB 1YBA). The N-terminus
of this PHGDH protein appears to be in a position that
would accommodate an epitope tag without disrupting
the core protein structure. Mycobacterium tuberculosis
PHGDH is an example of a type I protein [38] (PDB
1YGY). In contrast to the E. coli protein, M. tuberculosis
PHGDH is a tetramer formed by PHGDH monomers
with identical amino acid sequence but two different ter-
tiary structures. In the two monomer conformations, the
regulatory domains are rotated by 180°. This results in
inter-subunit interfaces that involve more complex
inter-subunit contacts than the E. coli structure [38].
Human PHGDH is also a type I protein, suggesting that
its structure may be more similar to M. tuberculosis
than E. coli. In the M. tuberculosis structure, the N-
terminus is not directly involved in any of the subunit-
subunit interfaces, but the increased complexity of the
Mattaini et al. Cancer & Metabolism  (2015) 3:5 Page 11 of 12interfaces may account for why placing a tag in this
position on the human protein affects structure and
function.
There remain a few possibilities for what PHGDH
function is disrupted by the N-terminal tag. A threshold
of PHGDH activity may be required to support prolifera-
tion, and despite retaining canonical enzyme activity, the
untagged version is less active and may not be able to
attain a level of activity required by proliferating cells.
Alternatively, PHGDH could have a non-canonical activ-
ity that has not been fully appreciated. The only known
PHGDH enzyme activity outside of serine synthesis is an
ability to generate small amounts of D-2HG. Because
N-terminally tagged PHGDH generates the same 2HG:αKG
ratio as untagged PHGDH, it is unlikely that a difference in
2HG production is responsible for the inability of tagged
enzyme to support proliferation. Furthermore, the inability
of tagged PHGDH to support cell proliferation despite pro-
duction of similar 2HG levels as the wild-type enzyme, even
in MDA-MB-231 cells, which express little to no endogen-
ous PHGDH, also argues against 2HG production as the
sole explanation for how increased PHGDH contributes to
cancer. If another unknown activity of PHGDH is necessary
to support proliferation, our results imply that it must also
be lost in the R236E mutant.
PHGDH has been proposed as a potential drug target in
cancer [42], and the impact of an epitope tag has practical
implications for designing screens for small-molecule
PHGDH inhibitors. Because tagged PHGDH retains some
enzyme activity, the convenience of generating recombin-
ant tagged protein might result in the use of this protein
for drug screening. Whether this will identify molecules
that impair proliferation of PHGDH-dependent cells re-
mains to be determined, but the use of recombinant un-
tagged protein is preferred based on our findings. If small
molecules are identified using either approach, they could
provide insight into whether the ability to inhibit 3-PG to
PHP conversion alone is the relevant PHGDH function in
cells and help understand the role of this enzyme in cell
proliferation and human cancer.Conclusions
Addition of an N-terminal epitope tag to PHGDH alters en-
zyme structure, reduces catalytic activity, and abrogates its
ability to support proliferation of PHGDH-dependent cancer
cells. A simple and effective scheme for purification of re-
combinant untagged PHGDH is presented, making use of
epitope tags to generate purified enzyme unnecessary.Additional files
Additional file 1: Figure S1. Western blot analysis of PHGDH
expression in the T.T. cells shown in Figure 2B.Additional file 2: Figure S2. In vitro enzyme activity and relative
specific activity of rHis-PHGDH and rFLAG-His-PHGDH. (A) In vitro enzyme
activity of rHis-PHGDH and rFLAG-His-PHGDH was assessed as in Figure 2A.
(B) Comparison of relative specific activity of rHis-PHGDH and rFLAG-His-
PHGDH. Error bars show standard deviation from the mean.
Additional file 3: Figure S3. Relative intracellular 2HG:αKG ratio as
measured by LC/MS. Error bars show standard error of the mean. P values
were calculated by a two-tailed Student’s t-test.
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